New CEO appointed at Nordic Nanovector
Nordic Nanovector have appointed Peter Braun as their new Chief Executive Officer.
Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and knowledge of pharmaceutical markets worldwide, from a career spanning nearly 30 years at Roche.
During his time at Roche, Braun led the Lifecycle Management teams for the successful targeted cancer therapies Herceptin (trastuzumab) and Tarceva (erlotinib). Outside of Roche, he also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies.
Mr Braun said: “I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that targeted cancer therapeutics represent an important treatment modality and well tolerated, targeted radiopharmaceuticals, such as Betalutin, can make a real difference to patients.”